Heart failure with preserved ejection fraction
Conditions
Interventions
Participants receive an echo-scan of the heart and several non-invasive vascular measurements. 
Sponsors
Amsterdam UMC
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Males and females aged 50-75 years at baseline; duration of T2DM of at least 1 year (defined on the basis of previous diagnosis and/or treatment with hypoglycaemic agents); with informed consent to be contacted for future research; able to provide a written consent form.Early-HFpEF baseline study visit was minimally three years ago.
Exclusion criteria
Exclusion criteria: 1. Advanced diabetes complications (like proliferative retinopathy, disabling polyneuropathy, or stages IV-V diabetic nephropathy). 2. Cardiac comorbidity: a) Valvular heart disease requiring surgery or intervention, or within 3 months after valvular surgery or intervention. b) Hypertrophic obstructive cardiomyopathy. c) Acute myocarditis, sarcoidosis, amyloidosis, Takotsubo cardiomyopathy. d) Post-heart transplant cardiomyopathy. e) Chronic HFrEF (a LV EF of
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Heart failure with preserved ejectionf fraction based on echocardiographic measurements, clinical measurements and biomarkers. | — |
Secondary
| Measure | Time frame |
|---|---|
| From 2025 onwards, we will also look at changes in these outcomes compared to the baseline study visit. | — |
Countries
Netherlands
Contacts
Public ContactRomain Meer
Amsterdam UMC
Outcome results
None listed